Abstract
Mepolizumab, an anti-interleukin-5 monoclonal antibody, reduces disease flares and blood eosinophil counts (BEC) in patients with hypereosinophilic syndrome (HES). We assessed the impact of baseline BEC on mepolizumab-associated flare reduction.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
